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Background and purpose: Genetic approaches have documented protein kinase B (PKB) as a pivotal regulator of heart
function. Insulin strongly activates PKB, whereas adrenaline is not considered a major physiological regulator of PKB in heart.
In skeletal muscles, however, adrenaline potentiates insulin-stimulated PKB activation without having effect in the absence of
insulin. The purpose of the present study was to investigate the interaction between insulin and b-adrenergic stimulation in
regulation of PKB phosphorylation.
Experimental approach: Cardiomyocytes were isolated from adult rats by collagenase, and incubated with insulin, isopre-
naline, and other compounds. Protein phosphorylation was evaluated by Western blot and phospho-specific antibodies.
Key results: Isoprenaline increased insulin-stimulated PKB Ser473 and Thr308 phosphorylation more than threefold in cardi-
omyocytes. Isoprenaline alone did not increase PKB phosphorylation. Isoprenaline also increased insulin-stimulated GSK-3b Ser9
phosphorylation approximately twofold, supporting that PKB phosphorylation increased kinase activity. Dobutamine (b1-
agonist) increased insulin-stimulated PKB phosphorylation as effectively as isoprenaline (more than threefold), whereas
salbutamol (b2-agonist) only potentiated insulin-stimulated PKB phosphorylation by approximately 80%. Dobutamine, but not
salbutamol, increased phospholamban Ser16 phosphorylation and glycogen phosphorylase activation (PKA-mediated effects).
Furthermore, the cAMP analogue that activates PKA (dibutyryl-cAMP and N6-benzoyl-cAMP) increased insulin-stimulated PKB
phosphorylation by more than threefold without effect alone. The Epac-specific activator 8-(4-chlorophenylthio)-2′-O-methyl-
cAMP (007) increased insulin-stimulated PKB phosphorylation by approximately 50%. Db-cAMP and N6-benzoyl-cAMP, but not
007, increased phospholamban Ser16 phosphorylation.
Conclusions and implications: b-adrenoceptors are strong regulators of PKB phosphorylation via cAMP and PKA when insulin
is present. We hypothesize that PKB mediates important signalling in the heart during b-adrenergic receptors stimulation.
British Journal of Pharmacology (2010) 160, 116–129; doi:10.1111/j.1476-5381.2010.00677.x; published online 23
March 2010
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Introduction
Genetic approaches have provided evidence that protein
kinase B (PKB or Akt) is an important regulator of normal
heart functions and dys-regulation causes cardiac disease
(Debosch et al., 2006). Deletion of PKBa decreases heart size
(Debosch et al., 2006) whereas overexpression of constitutively
activated PKB increases heart size and causes dilated myopathy
(Condorelli et al., 2002; Matsui et al., 2002). However, PKB has
beneficial effects and protects the hearts during ischaemia–
reperfusion (Matsui et al., 2002). Growth factors like insulin
and insulin-like growth factor-1 (IGF-1) activates PKB in the
heart (Chesley et al., 2000; Beauloye et al., 2001). Insulin acti-
vates PKB via PI 3-kinase (Shepherd et al., 1998; Shepherd,
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2005) and phosphorylation of PKB at Thr308 and at Ser473
(Vanhaesebroeck and Alessi, 2000). PDK1 phosphorylates PKB
Thr308 (Vanhaesebroeck and Alessi, 2000). PKB Ser473 is phos-
phorylated by mTORC2 complex in insulin-sensitive tissues
(Sarbassov et al., 2005), but DNA-PK, PKCbII and integrin-
linked kinase have been reported to phosphorylate PKB Ser473,
at least in some cell types (Persad et al., 2001; Kawakami et al.,
2004; Huston et al., 2008). Activated PKB phosphorylates gly-
cogen synthase kinase (GSK)-3 (GSK-3a Ser21 and GSK-3b Ser9)
and GSK-3 is, like PKB, a point of integration of hypertrophic
signalling in the heart (Sugden et al., 2008). Genetic manipu-
lations of regulators of PKB activity, like PDK1, PTEN and PI
3-kinase, have provided further evidence that regulation of
PKB signalling is essential for normal heart growth and func-
tion (Shioi et al., 2000; Schwartzbauer and Robbins, 2001;
Crackower et al., 2002; Mora et al., 2003; Bayascas et al., 2006;
Heineke and Molkentin, 2006).
b-Adrenoceptors regulate central physiological functions in
the heart (Ruehr et al., 2004; Zheng et al., 2005) and defective
cAMP regulation promotes heart failure (Lehnart et al., 2005).
The signalling pathways for b1- and b2-adrenoceptors differ
(Steinberg, 1999; Pavoine and Defer, 2005; Zheng et al., 2005).
Stimulation of b1-adrenergic receptors increases concentra-
tion of cAMP that activates PKA leading to phosphorylation
of phospholamban (PLB), ryanodine receptor, phosphorylase
kinase (which activates glycogen phosphorylase) and numer-
ous other proteins (Drago and Colyer, 1994; Steinberg, 1999).
In contrast, stimulation of b2-adrenoceptors is not thought to
increase PLB Ser16 phosphorylation or to activate glycogen
phosphorylase (Kuschel et al., 1999; Jo et al., 2002), although
a small increase in PLB Ser16 phosphorylation has been
observed (Bartel et al., 2003). Although b2-adrenergic recep-
tors activates adenylyl cyclase, the produced cAMP is rapidly
broken down (Xiang et al., 2005) and b2-adrenoceptors
mediate additional signalling via PI 3-kinase, extracellular
signal-regulated kinase (ERK) and phospholipase A2 (Stein-
berg, 2004; Pavoine and Defer, 2005). Interestingly, prolonged
stimulation of b1-adrenoceptors causes apoptosis in cardi-
omyocytes whereas b2-adrenoceptors may improve cell sur-
vival after hypoxia (Zhu et al., 2001; Zhu et al., 2003).
The g-isoform of class 1 PI 3-kinase (PI3Kg) is activated by G
protein-coupled receptors (Wymann and Marone, 2005) and
b-adrenoceptors have been reported to mediate effects via PI
3-kinase and PKB in heart cells (Chesley et al., 2000; Oudit
et al., 2003; Tseng et al., 2005). b2-Adrenoceptors activate
PI3Kg via Gai-coupled Gbg but PKB activation is much less than
during IGF-1 stimulation (Chesley et al., 2000). Recently,
cAMP has also been reported to mediate effect via exchange
protein directly activated by cAMP (Epac) (De rooij et al.,
1998; Jensen, 2007) and it has been reported that Epac medi-
ated hypertrophy in neonatal cardiomyocytes (Morel et al.,
2005; Métrich et al., 2008).
Stimulation of b2-adrenoceptors does not increase cAMP
concentration throughout the cell and compartmentalized
signalling allows activation of specific pools of PKA (Stein-
berg, 2004). A huge number of phosphodiesterases limit the
spread of cAMP and compartmentalize b2-adrenergic signal-
ling (Fischmeister et al., 2006). The PDE4 family is coded by
four genes comprising ~20 members (Houslay et al., 2005),
and the PDE4 subfamily is involved in establishing compart-
mentalized b2-adrenergic signalling in cardiomyocytes (Xiang
et al., 2005). ERK phosphorylates most PDE4 isoforms, and
ERK-mediated phosphorylation decreases phosphodiesterase
activity of the long isoforms whereas activity of most of the
short PDE4 isoforms increases (Mackenzie et al., 2000;
Houslay et al., 2005). The roles of ERK and PDE4 for
b2-adrenergic signalling have not achieved much attention in
cardiomyocytes from adult rats.
Recently, we reported complex interaction between
b-adrenoceptors and insulin signalling in skeletal muscles.
While b-adrenoceptor stimulation did not activate PKB in the
absence of insulin, b-adrenoceptor stimulation strongly
potentiated insulin-stimulated PKB phosphorylation and
activity, and cAMP mimicked the effect of b-adrenoceptor
stimulation (Brennesvik et al., 2005; Jensen et al., 2008). The
purpose of the present study was to test the hypothesis that
stimulation of b-adrenoceptors potentiates insulin-stimulated
PKB phosphorylation in cardiomyocytes via cAMP and PKA.
Methods
Chemicals and antibodies
Collagenase 2 and DNAse were from Worthington (Lakewood,
NJ, USA) and Natural Mouse Laminin from Invitrogen (Carls-
bad, CA, USA). Isoprenaline, dobutamine, salbutamol,
PD98,059, dibutyryl-cAMP (db-cAMP; #D0627), rolipram,
adrenaline, noradrenaline and wortmannin were from Sigma
(St. Louis, MO, USA). N6-Benzoyl-cAMP (N6-cAMP; B009),
8-(4-chlorophenylthio)-2′-O-methyl-cAMP (007; C041) and
8-Bromoadenosine-3′, 5′-cyclic monophosphorothioate,
Rp-isomer (Rp-8-Br-cAMPS; B001) were from BIOLOG Life
Science Institute (Bremen, Germany). Insulin (Actrapid) was
from Novo Nordisk (Bagsværd, Denmark). Anti-anti-GSK-3
(#05-412) and anti-mouse HRP-conjugate antibodies (#12-
349) were from Upstate (Lake Placid, NY, USA). Anti-phospho-
Akt Ser473 (#9271), anti-phospho-Akt Thr308 (#9275), anti-
phospho-GSK-3a/b Ser21/Ser9 (#9331) and anti-rabbit HRP-
linked antibodies (#7074) were from Cell Signaling
Technology (Danvers, MA, USA). Anti-PLB (#A010-14) and
anti-phospho-PLB Ser16 (A010-12) were from Badrilla (Leeds,
UK). ECL (RPN2106) was from Amersham Pharmacia (Buck-
inghamshire, UK) and ECL (WBKLS0500) from Millipore
(Bedford, MA, USA). Other chemicals were standard analytical
grades from Merck (Darmstadt, Germany), Sigma (St. Louis,
MO, USA) and Bio-Rad (Hercules, CA, USA).
Animals
Male Wistar rats were obtained from B & K Universal (Nit-
tedal, Norway) and acclimatized in our laboratory animal
facilities for 2 weeks with free access to food and tap water
before the experiment. Experiments were approved and con-
ducted in conformity with laws and regulations controlling
experiments and procedures for animal research in Norway
and the European Convention for the Protection of Vertebrate
Animals used in Experimental and Other Scientific Purposes.
Heart cell isolation and incubation
Hearts from adult male rats (450 g) were quickly removed
under pentobarbitone anaesthesia (0.8 mL pentobarbitone
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50 mg·mL-1 i.p.) and placed in ice-cold saline. The hearts
were, still immersed in saline, connected to the Langendorff
perfusion apparatus through a cannula inserted into the aorta
and cardiomyocytes were isolated by a procedure modified
after Stokke et al. (Stokke et al. 1996). The hearts were initially
perfused for ~10 min with a Ca2+-free Joklik S-MEM medium
(Invitrogen, 22300-016) added 24 mM NaHCO3, 1.2 mM
MgSO4, 1 mM DL-carnitine, pH 7.4 (buffer A). Perfusion was
continued for 25 min at 37°C with buffer A added 200 U·mL-1
collagenase 2 and 0.1% BSA at a flow rate of 6–7 mL·min-1
with recirculation. Perfusion buffers were gassed with 95%
O2/5% CO2. In some of the initial experiments trypsin
(63 U·mL-1, Sigma) was added. The effect of isoprenaline on
insulin-stimulated PKB phosphorylation was similar in cardi-
omyocytes isolated with and without trypsin and data are
pooled. The hearts were removed from the cannulae and the
ventricular tissue cut and torn into small fragments in 30 mL
buffer A added 0.5 mM CaCl2 and 1% BSA. Coagulated blood
and visible connective tissue were removed, and the suspen-
sion was incubated for 10 min, shaking (100 stroke per
minute), at 37°C and gently gassed. The heart tissue was
transferred to a glass tube and centrifuged (20¥ g, ~20 s). The
pellet was resuspended in 30 mL with buffer A added
200 U·mL-1 collagenase 2, 0.1% BSA and DNase I
(0.06 U·mL-1), and heart cells were allowed to dissociate for
15–20 min (shaking: 100 stroke per minute, 37°C and gently
gassed). Centrifugation was repeated and the cardiomyocyte
pellet resuspended in ~30 mL buffer A added 0.5 mM CaCl2
and 1% BSA, and allowed to rest at 37°C for 5 min without
agitation. The cell suspension was filtered through a nylon
mesh (size ~250 mm), centrifuged as above. The final pellet
containing the cardiomyocytes was resuspended in culture
medium (Medium 199 with 0.2% BSA, 2 mM DL-carnitine,
5 mM creatine, 5 mM taurine, 100 mU·mL-1 insulin, 1 ¥
10-10 M 5-triiodo-D-thyronine, 100 IU·mL-1 penicillin and
100 IU·mL-1 streptomycin; ~15 mL per heart). After
10–30 min at 37°C equilibrated with 95% O2/5% CO2, cardi-
omyocytes were plated in 9.5 cm2 TC dishes (Corning, NY,
USA) coated with laminin. After 2 h in incubator (37°C, 5%
CO2) in 2 mL culture medium the culture medium was
changed to remove non-attached cells and cell debris. After
change of medium, nearly all cells attached to laminin were
rod-shaped cardiomyocytes. The cardiomyocytes were incu-
bated overnight for experiments the following day. Protein
content within experiments was rather similar in each well. In
different experiment, mean protein content per well varied
between 400 and 800 mg. For laminin coating, dishes were
treated with 500 mL 10 mg·mL-1 laminin dissolved in Medium
199 for 1 h.
Prior to experiments, cardiomyocytes were preincubated for
2 h in 2 mL buffer containing 120 mM NaCl, 3.3 mM KCl,
1.2 mM KH2PO4, 24 mM NaHCO3, 0.8 mM MgSO4, 1 mM
CaCl2, 0.1% BSA, 5.5 mM D-glucose, pH 7.4 (PB). In experi-
ments, cardiomyocytes were incubated for 15 min in buffer as
above with or without insulin (10 000 mU·mL-1), isoprenaline
(10-6 M), dobutamine (10-6 M) or salbutamol (10-6 M). In
experiments with cAMP analogues and MEK inhibitor
(PD98,059), substances were added after 90 min of preincu-
bation. Cardiomyocytes were therefore incubated for 30 min
with PD98,059 (50 mM) or 0.5 mM of the cAMP analogues
(db-cAMP, N6-benzoyl cAMP or 007) prior to the 15 min incu-
bation with insulin (10 000 mU·mL-1) unless otherwise stated
in legends. In experiments with the PDE4 inhibitor rolipram
(1 mM) the inhibitor was added after 105 min of preincuba-
tion. Cardiomyocytes were therefore incubated with rolipram
for 15 min before insulin (10 000 mU·mL-1) and salbutamol
(10-6 M) were added for 15 min. PD98,059 and rolipram were
dissolved in DMSO; in these experiments, 0.1% DMSO was
included in wells.
Western blot analysis
Cardiomyocytes were scraped off the wells in 250 or
350 mL·well-1 of ice-cold lysis buffer containing 10 mM NaPO4
buffer pH 7.2, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1%
Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS (w/v),
0.2 mM Na3VO4 and 2 mL·mL-1 of protease inhibitor cocktail
(P8340; Sigma). The lysates were transferred to microtubes
and rotated for 45 min at 4°C. After centrifugation (11 600¥ g;
15 min; 4°C) protein concentration was determined in the
supernatant (DC Protein Assay, Bio-Rad, Hercules, CA, USA)
with protein standard from Sigma (P8119). Lysates were
diluted to equal concentration on experimental days
(1 mg·mL-1) and stored at -70°C.
For Western blot, lysates were prepared with Laemmli buffer
and proteins (~15 mg) were separated by electrophoresis
(Mini-PROTEAN 3 #165-3315 from Bio-Rad) in 10% SDS-
PAGE. A 15% SDS-PAGE was run for anti-PLB and anti-PLB
Ser16 probing. Proteins were transferred from gel into PVDF
membrane (Immobilon-P 0.45 mM, #IPVH00010 from Milli-
pore) for 1 h at 0.25 A with ice-container in transfer buffer
(25 mM Tris, 192 mM glycine and 10% methanol). Mem-
branes were washed 3 ¥ 10 min in PBS-T (80 mM NA2HPO4,
20 mM NaH2PO4, 100 mM NaCl and 0.1% Tween-20, pH 7.4)
and incubated (blocked) in 5% dried non-fat skim milk solved
in PBS-T for 2 h at room temperature to minimize non-
specific binding. All washing and incubation were done with
gentle shaking. Membranes were washed 2 ¥ 30 s in PBS-T
before incubation overnight at 4°C with primary antibodies
diluted in PBS-T with 3% BSA (w/v). Dilutions of primary
antibodies varied from 1:500 to 1:40 000. After 6 ¥ 10 min
wash, membranes were incubated at room temperature for
1 h with secondary antibody diluted in PBS-T with 1% BSA
(w/v). Dilutions of secondary antibodies varied from 1:20 000
to 1:40 000. After 6 ¥ 10 min wash, membranes were incu-
bated in ECL. Signals were detected from enhanced chemilu-
minescence after exposed to film (Kodak X-OMAT UV Plus
Film or FUJI RX Cat. nr. 90101104, Tokyo, Japan). The films
were scanned, and by using a densitometry the signals were
quantified (Scion Image, Scion Corporation).
Glycogen phosphorylase activity
Cardiomyocytes were scraped off the wells in 350 mL homog-
enizing buffer [50 mM MES, 100 mM NaF, 5 mM EDTA and
1 mM 2-mercaptoethanol (pH 6.1)]. The cell suspension was
minced in a MixerMill (Retsch, Haan, Germany) for 2 ¥ 30 s
and centrifuged (3000¥ g; 10 min; 4°C) and the supernatant
frozen at -70°C. Glycogen phosphorylase activity was mea-
sured in reverse direction with 48 mM glucose 1-phosphate
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and 0.5 mCi·mL-1 [14C(U)]-glucose 1-phosphate (PerkinElmer,
Shelton, CT, USA) by the filter paper method as described
previously (Gilboe et al., 1972; Franch et al., 1999). Total
phosphorylase activity was determined in the presence of
3 mM 5′-AMP in the assay buffer, phosphorylase a activity in
the absence of AMP, and percentage of phosphorylase in the
a-form was calculated. Total protein concentration in the
supernatant was determined (DC Protein Assay) using Protein
Standard (P8119, Sigma) as reference.
Statistics
Data are presented as mean  SE. Analysis of variance was
performed to investigate differences and Fishers least signifi-
cant difference was used as post hoc test to compare different
treatments. P < 0.05 was considered as significant.
Results
Protein kinase B Ser473 and Thr308 phosphorylation was not
detectable in cardiomyocytes incubated in buffer without
hormones. As expected, insulin increased phosphorylation of
PKB at both Ser473 and Thr308 (Figure 1). Isoprenaline did not
stimulate PKB Ser473 or Thr308 phosphorylation when present
alone. Interestingly, isoprenaline increased insulin-stimulated
PKB Ser473 and Thr308 phosphorylation by more than threefold
(Figure 1A and B). Insulin increased phosphorylation of
GSK-3b at Ser9 (PKB phosphorylation site) and combination of
insulin and isoprenaline increased GSK-3b Ser9 phosphoryla-
tion further supporting that PKB activity was increased
(Figure 1C). Dose–response curve for insulin-stimulated PKB
Thr308 phosphorylation in the presence and absence of isopre-
naline showed that isoprenaline also had a strong effect at
physiological concentrations of insulin (Figure 1F). Dose–
response curve for isoprenaline-mediated PKB Ser473 phospho-
rylation showed that high physiological concentrations of
isoprenaline were required to see effect on insulin-stimulated
PKB phosphorylation (Figure 1G). PLB Ser16 phosphorylation
(PKA phosphorylation site) was not detectable in basal con-
dition and during insulin stimulation. Isoprenaline increased
PLB Ser16 phosphorylation and insulin did not influence
isoprenaline-stimulated PLB Ser16 phosphorylation (Figure 1).
About 20% of glycogen phosphorylase was in a-form in basal
condition, and isoprenaline increased glycogen phosphory-
lase activation to about 55% (Table 1). Insulin decreased
isoprenaline-mediated glycogen phosphorylase activation
(Table 1) and tended to decrease basal glycogen phosphory-
lase activation (P = 0.091).
Wortmannin completely blocked PKB phosphorylation in
cardiomyocytes stimulated with insulin alone and combina-
tion of insulin and isoprenaline (Figure 2). In parallel with the
inhibited PKB phosphorylation, wortmannin also completely
blocked GSK-3b Ser9 phosphorylation stimulated by insulin
and isoprenaline (Figure 2).
The b1-agonist dobutamine and the b2-agonist salbutamol
were used to get indications of whether isoprenaline mediated
its effect via b1- or b2-adrenergic receptors. Dobutamine (b1-
agonist) increased insulin-stimulated PKB phosphorylation at
both Thr308 and Ser473 to similar level as isoprenaline did
(Figure 3A and B). Salbutamol (b2-agonist) also increased
insulin-stimulated PKB phosphorylation but was far less
potent than isoprenaline and dobutamine (Figure 3). Neither
dobutamine nor salbutamol increased PKB phosphorylation
in the absence of insulin. GSK-3b Ser9 phosphorylation was
high in cardiomyocytes incubated with insulin and dob-
utamine supporting that PKB phosphorylation increased
activity (Figure 3C). Salbutamol did not significantly activate
glycogen phosphorylase or phosphorylate PLB at Ser16 as
expected (Table 1; Figure 3D). Dobutamine, on the other
hand, increased glycogen phosphorylase activation and PLB
Ser16 phosphorylation (Table 1; Figure 3D). Adrenaline and
noradrenaline increased insulin-stimulated PKB Ser473, PKB
Thr308 and GSK-3b Ser9 phosphorylation in a similar manner
as isoprenaline (Figure 3E). Moreover, adrenaline and norad-
renaline increased PLB Ser16 phosphorylation (Figure 3E). In
the absence of insulin, adrenaline and noradrenaline did not
influence PKB or GSK-3b phosphorylation (Figure 3E).
The cAMP analogue db-cAMP mimicked the effect of iso-
prenaline on PKB phosphorylation. Alone, db-cAMP did not
increase PKB phosphorylation, but db-cAMP potentiated
insulin-stimulated PKB Ser473 and Thr308 phosphorylation
(Figure 4A and B). GSK-3b Ser9 phosphorylation was also
higher in cardiomyocytes incubated with db-cAMP and
insulin compared with cardiomyocytes incubated with
insulin alone (Figure 4C). N6-cAMP, a PKA-selective cAMP
analogue, also increased insulin-stimulated PKB Ser473 and
Thr308 phosphorylation approximately fourfold without
having effect alone (Figure 4A and B). N6-cAMP (0.5 mM)
increased glycogen phosphorylase activation (Table 1) and
caused PLB Ser16 phosphorylation (Figure 4D). The Epac-
specific cAMP analogue 007 increased insulin-stimulated PKB
phosphorylation by about 80% (Figure 4). The Epac activator
(0.5 mM) did not activate glycogen phosphorylase (Table 1)
or stimulate PLB Ser16 phosphorylation (Figure 4D) support-
ing that PKA was not activated.
Inhibition of PKA with Rp-8-Br-cAMPS (0.5 mM) reduced
glycogen phosphorylase activation in cardiomyocytes incu-
bated with 3 ¥ 10-9 M isoprenaline from 32.1  1.4% to 27.4
 1.6% (P < 0.05; n = 4 in both groups). Rp-8-Br-cAMPS also
reduced PKB Ser473 phosphorylation in cardiomyocytes incu-
bated with insulin and isoprenaline (Figure 5) whereas Rp-8-
Br-cAMPS did not influence insulin-stimulated PKB Ser473
phosphorylation (Figure 5).
PDE4 is required for b2-adrenoceptor subtype-specific sig-
nalling in cardiomyocytes (Xiang et al., 2005). Furthermore,
a large complex consisting of PDE4, ERK, MEK, mAKAP, Epac
and PKA has been reported to exist in neonatal cardiomyo-
cytes (Dodge-kafka et al., 2005). In the present study, we used
rolipram (PDE4 inhibitor) and PD98,059 (MEK inhibitor) to
test the hypothesis that ERK-mediated PDE4 phosphoryla-
tion reduced the ability of b2-adrenoceptor stimulation to
increase insulin-stimulated PKB phosphorylation. Rolipram
increased PKB phosphorylation when cardiomyocytes were
incubated with both insulin and salbutamol (Figure 6A and
B). Rolipram also increased GSK-3b Ser9 phosphorylation in
heart cells incubated with both salbutamol and insulin
(Figure 6C). Inhibition of PDE4 by rolipram did not increase
PLB Ser16 phosphorylation in basal condition but increased
PLB Ser16 phosphorylation when salbutamol was present
cAMP-PKA signalling regulates PKB in heart
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(Figure 6D). Rolipram did not influence basal or insulin-
stimulated PKB phosphorylation. Inhibition of MEK by
PD98,059 increased PKB Ser473, PKB Thr308 and GSK-3 Ser9
phosphorylation in cardiomyocytes when both insulin and
salbutamol were present (Figure 7A–C). PD98,059 also
increased salbutamol-mediated PLB Ser16 phosphorylation
(Figure 7D) supporting that PKA became activated. Basal and
insulin-stimulated PKB Ser473 phosphorylation was not influ-
enced by PD98,059.
Discussion
A novel and important finding in the present study was that
stimulation of b-adrenergic receptors increased insulin-
stimulated PKB phosphorylation in cardiomyocytes. Interest-
ingly, stimulation of b1-adrenergic receptors increased insulin-
stimulated PKB phosphorylation (>300%) much more than
stimulation of b2-adrenergic receptor (~80%). Furthermore,
the cAMP analogues activating PKA (db-cAMP and N6-cAMP)
increased insulin-stimulated PKB as much as isoprenaline. In
addition, the Epac-specific cAMP analogue 007 increased
insulin-stimulated PKB phosphorylation although to lesser
extent. Our findings couples for the first time b-adrenoceptor-
cAMP-PKA signalling to stimulation of PKB phosphorylation
in cardiomyocytes and indicates the need to reconsider the
role of b-adrenergic receptor in the regulation of PKB. In
particular, studies of b-adrenoceptor signalling in heart need
to take into account the potential synergistic crosstalk with
other hormones.
Insulin is considered a strong activator of PKB (Bertrand
et al., 2008) and it is therefore notable that stimulation of
b-adrenoceptors increased insulin-stimulated PKB Ser473 and
Thr308 phosphorylation by three- to fourfold. Isoprenaline
also increased insulin-stimulated GSK-3b Ser9 phosphoryla-
tion supporting that PKB activity was increased, and our data
suggest that b-adrenoceptors are powerful regulators of PKB
when insulin is present. PKB has a central role for regulation
of cardiac function and it has been shown that overexpression
of constitutively activated PKB increases heart size and causes
dilated myopathy (Condorelli et al., 2002; Matsui et al., 2002)
whereas deletion of PKBa decreases heart size (Debosch et al.,
2006). Furthermore, PKB protects the hearts during
ischaemia–reperfusion (Matsui et al., 2002) and regulates
Figure 1 Effect of isoprenaline and insulin on phosphorylation of protein kinase B (PKB), glycogen synthase kinase (GSK)-3b and phospho-
lamban (PLB) in isolated cardiomyocytes. After an overnight incubation in medium, cardiomyocytes were preincubated in buffer without any
hormones for 2 h prior to 15 min incubation with or without isoprenaline (10-6 M) in the absence or presence of insulin (10 000 mU·mL-1).
Cardiomyocytes were prepared for Western blot as described in Methods. (A) Effect of isoprenaline and insulin on PKB Ser473 phosphorylation.
Graph shows means of quantified blots with insulin as 100%; data are from three different experiments; n = 6–9 in each group; representative
blot is shown in (E). (B) Effect of isoprenaline and insulin on PKB Thr308 phosphorylation. Graph shows means of quantified blots with insulin
as 100%; data are from three different experiments; n = 6–7 in each group. (C) Effect of isoprenaline and insulin on phosphorylation GSK-3b
Ser9 phosphorylation. Graph shows means of quantified blots with insulin as 100%; data are from three different experiments; n = 6–7 in each
group. (D) Effect of isoprenaline and insulin on PLB Ser16 phosphorylation. Graph shows means of quantified blots with isoprenaline as 100%;
data are from four different experiments; n = 8–9 in each group. (E) Representative blots showing PKB Ser473, PKB Thr308, GSK-3b Ser9, PLB Ser16
phosphorylation and total GSK-3b and total PLB in different treatments groups. (F) Dose–response curve for insulin-stimulated PKB Ser308
phosphorylation in the absence (open circles) and presence of 10-6 M isoprenaline (filled squares); symbols are means of quantified blots (with
10 000 mU·mL-1 of insulin as 100%) from three different experiments; n = 9 for insulin 10 000 mU·mL-1 and n = 6 for other symbols. (G)
Dose–response curve for isoprenaline-mediated PKB Ser473 phosphorylation in the presence of 10 000 mU·mL-1 insulin; symbols are means of
quantified blots (with insulin as 100%) from four different experiments; n = 19 for insulin and n = 9–12 for other symbols. aSignificantly higher
than insulin.

Table 1 Glycogen phosphorylase activation in cardiomyocytes after
exposure to b-adrenergic receptor agonists or cAMP analogues
Glycogen phosphorylase (% a-form)
(-) Insulin (+) Insulin
Control 20.9  0.9 (22) 18.1  0.8 (12)
Isoprenaline 55.5  1.4a (21) 42.3  0.4b (6)
Dobutamine 39.6  1.9a,b (12)
Salbutamol 23.9  1.2 (6)
N6-cAMP 45.6  3.2a (8)
007 22.8  2.2 (6)
Cardiomyocytes were incubated overnight in medium and preincubated for
2 h in buffer without any hormones prior to 15 min exposure to isoprenaline
(10-6 M), dobutamine (10-6 M) salbutamol (10-6 M) and insulin
(10 000 mU·mL-1). Cardiomyocytes were exposed to 0.5 mM of the cAMP
analogues for 45 min. Adrenaline and noradrenaline increased glycogen phos-
phorylase %a to 46.2  2.4 and 49.4  1.1 respectively (n = 4 in both groups;
P < 0.05 compared with control).
Data are mean  SEM. Number of samples in parentheses.
aSignificantly higher than control and salbutamol.
bSignificantly lower than isoprenaline without insulin.
007, 8-(4-chlorophenylthio)-2′-O-methyl-Camp; N6-cAMP, N6-benzoyl-cAMP.
Figure 2 Wortmannin blocks phosphorylation of protein kinase B
(PKB) and glycogen synthase kinase (GSK)-3b stimulated by insulin
alone and in combination with isoprenaline. Representative blots for
PKB Ser473, PKB Thr308 and GSK-3b Ser9 phosphorylation in cardi-
omyocytes incubated with insulin (10 000 mU·mL-1), isoprenaline
(10-6 M) and wortmannin as indicated. After an overnight incubation
in medium, cardiomyocytes were preincubated in buffer without any
hormones for 2 h with 1 mM wortmannin added after 105 min. After
preincubation (and 15 min incubation with wortmannin) insulin and
isoprenaline was added for 15 min.
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Figure 3 Effect of dobutamine (b1-agonist), salbutamol (b2-agonist), isoprenaline, adrenaline and noradrenaline on insulin-stimulated protein
kinase B (PKB), glycogen synthase kinase (GSK)-3b and phospholamban (PLB) phosphorylation. After an overnight incubation in medium,
cardiomyocytes were preincubated in buffer without any hormones for 2 h prior to 15 min incubation with salbutamol (10-6 M), dobutamine
(10-6 M), isoprenaline (10-6 M), adrenaline (10-6 M) and noradrenaline (10-6 M) in the absence or presence of insulin (10 000 mU·mL-1).
Graphs show means of quantified blots with insulin as 100%; representative blots are shown in (D). (A) Effect of dobutamine, salbutamol and
isoprenaline on insulin-stimulated PKB Ser473 phosphorylation. Data are from five different experiments; n = 20 for insulin and n = 10–14 for
other groups. (B) Effect of dobutamine, salbutamol and isoprenaline on insulin-stimulated PKB Thr308 phosphorylation. Data are from five
different experiments; n = 18 for insulin and n = 8–11 for other groups. (C) Effect of dobutamine, salbutamol and isoprenaline on
insulin-stimulated GSK-3b Ser9 phosphorylation. Data are from five different experiments; n = 17 for insulin and n = 8–11 for other groups. (D)
Representative blots showing PKB Ser473, PKB Thr308, GSK-3b Ser9 and PLB Ser16 phosphorylation and total PKB in different treatments groups.
(E) Representative blots showing PKB Ser473, PKB Thr308, GSK-3b Ser9 and PLB Ser16 phosphorylation in cardiomyocytes incubated with
adrenaline (10-6 M) and noradrenaline (10-6 M) alone or in combination with insulin. aSignificantly higher than insulin; bSignificantly higher
than insulin + salbutamol.
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Figure 4 Effect of cAMP analogues on phosphorylation of protein kinase B (PKB), glycogen synthase kinase (GSK)-3b and phospholamban
(PLB). After an overnight incubation in medium, cardiomyocytes were preincubated in buffer without any hormones for 2 h with cAMP
analogues (0.5 mM) added after 90 min. After preincubation (and 30 min incubation with cAMP analogues) insulin was added for 15 min.
Graphs show means of quantified blots with insulin as 100%; representative blots are shown in (D). (A) Effect of cAMP analogues on PKB Ser473
phosphorylation in the absence or presence of 10 000 mU·mL-1 insulin. Data are from five different experiments; n = 19 for insulin and n = 10
for other groups. (B) Effect of cAMP analogues on PKB Thr308 phosphorylation in the absence or presence of 10 000 mU·mL-1 insulin. Data are
from five different experiments; n = 19 for insulin and n = 10 for other groups. (C) Effect of cAMP analogues on GSK-3b Ser9 phosphorylation
in the absence or presence of 10 000 mU·mL-1 insulin. Data are from five different experiments; n = 27 for insulin and n = 10 for other groups.
(D) Representative blots showing PKB Ser473, PKB Thr308, GSK-3b Ser9 and PLB Ser16 phosphorylation and total PKB in different treatments
groups. aSignificantly higher than insulin; bSignificantly higher than insulin + 007; cSignificantly higher than insulin + N6-cAMP. *Significantly
lower than insulin. 007, 8-(4-chlorophenylthio)-2′-O-methyl-cAMP; db-cAMP, dibutyryl-cAMP; N6-cAMP, N6-benzoyl-cAMP.
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other functions in the heart (Shiojima and Walsh, 2006).
Although we mainly used GSK-3 Ser9 phosphorylation as a
readout of PKB activity, it is worth to note that GSK-3 per se is
considered as a key hypertrophic signalling molecule in the
heart (Sugden et al., 2008). Taken together, our data show that
stimulation of b-adrenoceptors, in the presence of insulin,
strongly increases phosphorylation of the two hypertrophic
signalling molecules PKB and GSK-3.
Isoprenaline alone did not significantly increase PKB phos-
phorylation in cardiomyocytes from adult rats. Previously,
b-adrenergic stimulation has been reported to increase PKB
Ser473 phosphorylation in neonatal cardiomyocytes (Chesley
et al., 2000; Morisco et al., 2005) and in H9c2 cardiomyocytes
(Yano et al., 2007). However, b-adrenoceptor-mediated PKB
activation is low compared with IGF (Chesley et al., 2000) and
b-adrenoceptors are normally not considered as an important
regulator of PKB in the heart (Shiojima and Walsh, 2006).
Indeed, in vivo injection of isoprenaline has also shown to
increase PKB phosphorylation in adult rats (Tseng et al., 2005)
and mice (Oudit et al., 2003); in vivo insulin will always be
present and it is possible that the effect of isoprenaline rep-
resents a potentiation of insulin action. Leblais et al. (Leblais
et al. 2004) have also reported that stimulation of
b1-adrenoceptors increase PI 3-kinase activity, but data on PKB
were not reported. Even though these data seem to contradict
the finding that b-adrenoceptor stimulation did not increase
PKB phosphorylation in the absence of insulin, we have pre-
viously reported similar effect of b-adrenergic stimulation on
PKB phosphorylation in skeletal muscles: adrenaline had no
effect in the absence of insulin but potentiated insulin-
stimulated PKB phosphorylation and activity (Brennesvik
et al., 2005; Jensen et al., 2008). In the present study, adrena-
line and noradrenaline increased insulin-stimulated PKB
phosphorylation as efficiently as isoprenaline, supporting a
physiological role of the sympathoadrenal system in the regu-
lation of PKB in the heart.
Stimulation of b1-adrenoceptors increased insulin-
stimulated PKB phosphorylation much more than stimula-
tion of b2-adrenoceptors. This was not expected since
b2-adrenoceptor stimulation, previously has been coupled to
PKB activation (Chesley et al., 2000; Oudit et al., 2003; Tseng
et al., 2005), but not b1-adrenoceptor stimulation. It is well
documented that b1- and b2-adrenoceptors have different sig-
nalling mechanism in cardiomyocytes from adult rats (Stein-
berg, 1999; Pavoine and Defer, 2005; Zheng et al., 2005). In
agreement with these studies, we found that stimulation of
b1-adrenergic receptors agonist dobutamine increased glyco-
gen phosphorylase activation and PLB Ser16 phosphorylation
whereas salbutamol did not significantly activate glycogen
phosphorylase and phosphorylates PLB Ser16 (Kuschel et al.,
1999; Jo et al., 2002). The physiological role of b1- and
b2-adrenoceptors also differs and it has been reported that
stimulation of b1-adrenoceptors causes apoptosis whereas
stimulation of b2-adrenoceptors prevents apoptosis (Commu-
nal et al., 1999; Zhu et al., 2001; Zhu et al., 2003). Because
activation of PKB prevents apoptosis, it was exciting that
addition of insulin made b1-adrenoceptor stimulation to a
powerful activator of PKB phosphorylation. Furthermore,
b1-adrenoceptors stimulates hypertrophy much more than
b2-adrenoceptors, and our results raise the possibility that
b1-adrenoceptors mediate hypertrophic signalling via PKB and
GSK-3.
We hypothesized that b-adrenoceptors potentiated insulin-
stimulated PKB phosphorylation via cAMP; the hypothesis
was supported by the fact that db-cAMP increased insulin-
stimulated PKB phosphorylation. To further dissect the sig-
nalling pathway we used the PKA-specific cAMP analogues
N6-cAMP, which strongly increased insulin-stimulated PKB
phosphorylation without having effect alone and therefore
mimicked the effect of isoprenaline on PKB phosphorylation.
Moreover, the cAMP analogue Rp-8-Br-cAMPS, which pre-
vents PKA activation, reduced PKB Ser473 phosphorylation in
cardiomyocytes incubated with insulin and isoprenaline.
These data show for the first time that cAMP increases PKB
phosphorylation via PKA in heart. Both PKB and cAMP sig-
nalling has previously been reported to mediate dilated car-
diomyopathy (Lehnart et al., 2005; Shiojima and Walsh,
2006). Our findings now couples cAMP and PKA signalling to
phosphorylation of PKB, and links the two hypertrophic sig-
nalling pathways in heart that were previously regarded as
independent.
The Epac-specific cAMP analogue 007 also increased
insulin-stimulated PKB phosphorylation in heart, but less
than db-cAMP and N6-cAMP. The fact that 007 did not stimu-
late PLB Ser16 phosphorylation or activate glycogen phospho-
rylase supports that the effect was specific for Epac, and our
data suggest that both PKA and Epac increase insulin-
stimulated PKB phosphorylation. In skeletal muscles, we
reported that 007 increased insulin-stimulated PKB phospho-
rylation (Brennesvik et al., 2005), and suggested that the effect
was mediated via Epac only because the PKA inhibitor H89
further increased the adrenaline-mediated potentiation of
Figure 5 The protein kinase A (PKA) inhibitor Rp-8-Br-cAMPS
reduces PKB Ser473 phosphorylation in cardiomyocytes incubated
with insulin and isoprenaline. After an overnight incubation in
medium, cardiomyocytes were preincubated in buffer for 3 h with
Rp-8-Br-cAMPS (0.5 mM) and without any hormones. After preincu-
bation insulin (10 000 mU·mL-1) and isoprenaline (3 ¥ 10-9 M) was
added for 15 min. Data are from three different experiments; n = 6–7
for all groups. Representative blots for PKB Ser473 and total PKB are
shown above the graph. aSignificantly higher than insulin; bSignifi-
cantly lower than insulin + isoprenaline.
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insulin-stimulated PKB phosphorylation. However, H89 is a
rather unspecific inhibitor for PKA (Lochner and Moolman,
2006), and we have later seen that N6-cAMP increases insulin-
stimulated PKB phosphorylation in soleus muscles (J. Jensen,
unpublished). Therefore, we suspect that H89 influences PKB
phosphorylation via mechanisms independent of PKA and
there are no contradictions between the studies. Our data
suggest that activation of both PKA and Epac can increase
insulin-stimulated PKB phosphorylation in cardiomyocytes
from adult rats. However, Epac seems much less effective
than PKA.
The mechanism for PKA-mediated PKB phosphorylation is
not obvious, but requires PI 3-kinase activation as wortman-
nin completely blocked PKB and GSK-3 phosphorylation in
cardiomyocytes stimulated with insulin and isoprenaline. A
possibility is that b-adrenoceptor stimulation increased
insulin-stimulated PI 3-kinase activity, but this does not
occur in skeletal muscles where stimulation of
b-adrenoceptors also potentiated insulin-stimulated PKB and
GSK-3 phosphorylation (Brennesvik et al., 2005; Jensen
et al., 2007; Jensen et al., 2008). Therefore, it is also likely
that stimulation of b-adrenoceptors regulate other compo-
nents in the PI 3-kinase signalling pathway such as PTEN,
PDK1, mTORC2 or the phosphatase that dephosphorylates
PKB; this idea is supported by a recent study showing that
inhibition of PKA attenuated PDGF-mediated PIP3 accumu-
lation independent of PI 3-kinase activity in fibroblasts
(Deming et al., 2008). It is also possible that b-adrenoceptor
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Figure 6 Rolipram increases phosphorylation of protein kinase B (PKB), glycogen synthase kinase (GSK)-3b and phospholamban (PLB) in
cardiomyocytes incubated with salbutamol and insulin. After an overnight incubation in medium, cardiomyocytes were preincubated in buffer
without any hormones for 2 h with 1 mM rolipram added after 105 min. After preincubation (and 15 min incubation with 1 mM rolipram)
insulin (10 000 mU·mL-1) and salbutamol (10-6 M) were added for 15 min. Graph shows means of quantified blots with insulin as 100%;
representative blot is shown in (D). (A) Effect of rolipram on insulin-stimulated PKB Ser473 phosphorylation in the absence or presence of
salbutamol. Data are from four different experiments; n = 16 for insulin and n = 7–15 for other groups. (B) Effect of rolipram on
insulin-stimulated PKB Thr308 phosphorylation in the absence or presence of salbutamol. Data are from six different experiments; n = 22 for
insulin and n = 9–12 for other groups. (C) Effect of rolipram on insulin-stimulated GSK-3b Ser9 phosphorylation in the absence or presence of
salbutamol. Data are from six different experiments; n = 24 for insulin and n = 9–12 for other groups. (D) Representative blots showing PKB
Ser473, PKB Thr308, GSK-3b Ser9 and PLB Ser16 phosphorylation and total GSK-3b and PLB in different treatments groups. aSignificantly higher
than insulin; bSignificantly higher than insulin + salbutamol.
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stimulation activates other kinases, like DNA-PK, PKCb2 or
integrin-linked kinase, which have been reported to phos-
phorylate PKB Ser473 in some cell types (Persad et al., 2001;
Kawakami et al., 2004; Huston et al., 2008). Although the
present study does clarify the mechanisms by which
b-adrenoceptor stimulation increases insulin-stimulated PKB
phosphorylation in cardiomyocytes, our data show that the
PI 3-kinase activation is involved.
PDE4 is required for b2-adrenoceptor subtype-specific sig-
nalling in cardiomyocytes (Xiang et al., 2005). ERK phospho-
rylates most PDE4 isoforms and phosphorylation decreases
phosphodiesterase activity of the long isoforms whereas activ-
ity of most of the short isoforms increases (Mackenzie et al.,
2000; Houslay et al., 2005). In the present study, we used
rolipram (PDE4 inhibitor) and PD98,059 (MEK inhibitor) to
test the hypothesis ERK-mediated PDE4 phosphorylation
reduced the ability of b2-adrenoceptor stimulation to increase
insulin-stimulated PKB phosphorylation. Interestingly, inhi-
bition of PDE4 (rolipram) or MEK (PD98,059) increased the
effect of salbutamol on insulin-stimulated PKB phosphoryla-
tion. Rolipram and PD98,059 also increased PLB Ser16 when
salbutamol was present supporting that PKA became acti-
vated. These data also support that stimulation of
b2-adrenoceptors activate adenylyl cyclase in adult rat cardi-
omyocytes, but the produced cAMP is broken down immedi-
ately by PDE4 in a process that requires ERK activation.
Unfortunately, the present study does not determine which
isoforms of ERK and PDE4 that mediate this effect in adult
cardiomyocytes. Compartmentalized b2-adrenergic signalling
involves PDE4 in large protein complexes (Baillie and
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Figure 7 The MEK inhibitor PD98,059 increases phosphorylation of protein kinase B (PKB), glycogen synthase kinase (GSK)-3b and
phospholamban (PLB) in cardiomyocytes incubated with salbutamol and insulin. After an overnight incubation in medium, cardiomyocytes
were preincubated in buffer without any hormones for 2 h with 50 mM PD98,059 added after 90 min. After preincubation (and 30 min
incubation with 50 mM PD98,059) insulin (10 000 mU·mL-1) and salbutamol (10-6 M) were added for 15 min. Graph shows means of quantified
blots with insulin as 100%; representative blot is shown in (D). (A) Effect of PD98,059 on insulin-stimulated PKB Ser473 phosphorylation in the
absence or presence of salbutamol. Data are from three different experiments; n = 10 for insulin and n = 4–6 for other groups. (B) Effect of
PD98,059 on insulin-stimulated PKB Thr308 phosphorylation in the absence or presence of salbutamol. Data are from five different experiments;
n = 16 for insulin and n = 7–10 for other groups. (C) Effect of PD98,059 on insulin-stimulated GSK-3b Ser9 phosphorylation in the absence or
presence of salbutamol. Data are from four different experiments; n = 14 for insulin and n = 6–8 for other groups. (D) Representative blots
showing PKB Ser473, PKB Thr308, GSK-3b Ser9 and PLB Ser16 phosphorylation and total PKB and PLB in different treatments groups. aSignificantly
higher than insulin; bSignificantly higher than insulin + salbutamol.
cAMP-PKA signalling regulates PKB in heart
126 JT Stuenæs et al
British Journal of Pharmacology (2010) 160 116–129
Houslay, 2005) and Dodge-Kafka et al. recently reported a
large complex consisting of PDE4, ERK, MEK, mAKAP, Epac
and PKA in neonatal cardiomyocytes (Dodge-kafka et al.,
2005). The data in the present study support that ERK-
mediated phosphorylation of PDE4 contribute to compart-
mentalization of b2-adrenoceptor signalling in adult
cardiomyocytes and reduce PKA-mediated potentation of
insulin-stimulated PKB phosphorylation.
A clear limitation of the present study is that we do not
describe a complete signalling pathway for the increase in
insulin-stimulated PKB phosphorylation during stimulation
of b-adrenoceptors. However, the present study for the first
time report that cAMP-mediated PKA activation increases PKB
phosphorylation in cardiomyocytes. It is also a limitation that
we do not report a physiological role of b-adrenoceptor-
mediated potentation of insulin-stimulated PKB phosphory-
lation. However, the fact that isoprenaline-mediated PKB
phosphorylation depends on insulin in cardiomyocytes high-
lights that insulin should be included in studies with
b-adrenoceptor agonist, and it would be particular interesting
to investigate whether stimulation of b1-adrenoceptors still
causes apoptosis in cardiomyocytes when insulin is present.
The present study also opens new perspectives. Defective
regulation of both PKB and cAMP signalling have been
coupled to cardiac hypertrophy (Zheng et al., 2005), and the
crosstalk between cAMP-PKA and PKB now couples these
two pathways. cAMP signalling has, to the best of our
knowledge, not been coupled to PI3Kg activation, and it is
therefore appealing to speculate that cAMP-mediated PKB
phosphorylation may involves class I A PI 3-kinase. Crack-
ower et al. (Crackower et al. 2002) reported that cardiac spe-
cific deletion of PTEN induced cardiac hypertrophy via
PI3Ka and elevated PKB phosphorylation, and it is possible
that combined activation of insulin and b-adrenoceptor sig-
nalling may induce cardiac hypertrophy via this signalling
pathway. Metabolic syndrome is associated with increased
sympathetic nervous activity and hyperinsulinemic and it
may be attractive to hypothesize that this interaction
between insulin and b-adrenoceptor signalling contributes
to the increased risk for development of heart failure in type
2 diabetes (Ashrafian et al., 2007). Moreover, as PKB activa-
tion improves recovery from ischaemia–reperfusion (Matsui
et al., 2001), it would also be relevant to investigate whether
combination of insulin and b-adrenoceptor will improve
recovery from ischaemia. The crosstalk mechanisms between
insulin and b-adrenoceptors in the regulation of PKB should
be fully characterized in the heart, as they may represent
novel targets for treatment of cardiac diseases.
In conclusion, b-adrenoceptors are powerful regulators of
PKB phosphorylation in the presence of insulin. The poten-
tiation of insulin-stimulated PKB phosphorylation occurs via
cAMP and PKA, and stimulation of b1-adrenergic receptors
increased insulin-stimulated PKB phosphorylation much
more than b2-adrenergic receptor stimulation. Stimulation of
b2-adrenoceptors activates adenylyl cyclase but co-activation
of PDE4 prevents cAMP accumulation and PKA activation in
adult rat cardiomyocytes. Moreover, the crosstalk between
insulin and b-adrenergic receptors in cardiomyocytes show
that it is important to study b-adrenergic signalling in the
presence of insulin or other growth factors.
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